- Home
- DSP vs NMRA Comparison
DSP vs NMRA Comparison
Compare DSP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DSP | NMRA |
|---|---|---|
| Founded | 1999 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.3M | 424.4M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | DSP | NMRA |
|---|---|---|
| Price | $11.63 | $1.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $18.50 | $8.00 |
| AVG Volume (30 Days) | 234.0K | ★ 980.8K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.49 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $324,131,000.00 | N/A |
| Revenue This Year | $17.79 | N/A |
| Revenue Next Year | $17.72 | N/A |
| P/E Ratio | $118.61 | ★ N/A |
| Revenue Growth | ★ 22.97 | N/A |
| 52 Week Low | $8.11 | $0.61 |
| 52 Week High | $26.33 | $11.57 |
Technical Indicators
Market Signals| Indicator | DSP | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 64.39 | 36.56 |
| Support Level | $11.07 | $2.05 |
| Resistance Level | $12.48 | $2.36 |
| Average True Range (ATR) | 0.50 | 0.14 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 66.13 | 3.12 |
Price Performance
Historical ComparisonAbout DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.